Perrigo Says 'Spray Hello' To Beco With UK Brand Revitalization Campaign
Perrigo relaunches OTC nasal sprays under single 'Beco' brand supported by £1.7m multimedia marketing campaign.
You may also be interested in...
Two UK advertising complaint verdicts delivered by the MHRA, Reckitt Benckiser's Nurofen Express (upheld) and Perrigo's Solpadeine Max (not upheld).
As "market leader" in OTC nicotine replacement treatments, Perrigo should "be the one that's doing a lot of innovation," says CEO Murray Kessler. He discussed Perrigo's problems and potential sales drivers as it reported 2018 net sales of $4.7bn, down 4% , and Q4 net sales of $1.2bn, down 7%. Global consumer health product sales for year were flat at $3.9bn and Q4 sales were down 4% at $973m.
Perrigo has launched a UK pharmacy-facing trade campaign for Nytol to help pharmacists and pharmacy-staff get over their misconceptions about sleep aids and have better conversations with consumers about their sleep problems.